PS48 Sensitizes Neurons to Insulin for Alzheimer's Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, particularly those targeting amyloid hypothesis, have shown disappointing results, and there is a need for effective methods to address neuronal insulin resistance and related cognitive decline.
Innovation Solution
The use of (Z)-5-(4-chlorophenyl)-3-phenylpent-2-enoic acid, known as PS48, which sensitizes neurons to insulin or insulin-like growth factor 1, thereby restoring normal insulin pathway regulation and mitigating the toxic effects of intracellular beta-amyloid peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-amyloid agents (inhibitors of γ-secretase and β-secretase, passive immunotherapies) are used to prevent AD progression, then amyloid plaque deposits are reduced, but overall treatment results are disappointing and do not sufficiently address neuronal insulin resistance
Solution Approach 1:
The compound PS48 is designed to simultaneously address multiple pathological mechanisms in Alzheimer's disease: it sensitizes neurons to insulin, restores insulin signaling pathways, reduces intracellular beta-amyloid accumulation, and improves neuronal viability. This multi-functional approach overcomes the limitation of single-mechanism anti-amyloid agents by providing comprehensive treatment that targets both amyloid pathology and insulin resistance concurrently.
Solution Approach 2:
The invention changes the therapeutic parameter from solely targeting amyloid production/removal to targeting insulin sensitivity and neuronal metabolic function. By using PS48 to restore insulin signaling parameters (Akt activation, glucose metabolism) while simultaneously reducing beta-amyloid levels, the treatment achieves broader efficacy against the multifactorial pathology of Alzheimer's disease.
2Reliability
If insulin signaling pathways are restored to improve neuronal viability, then cognitive function improves, but overstimulation of PI3K/Akt signaling may occur
Solution Approach 1:
PS48 acts as an insulin sensitizer that restores defective insulin signaling feedback loops in Alzheimer's neurons. By improving the sensitivity of insulin receptors and downstream signaling components (IRS, PI3K, Akt) rather than directly overactivating them, the compound re-establishes physiological feedback control. This allows the cell's own regulatory mechanisms to prevent overstimulation while still achieving therapeutic restoration of signaling function.
Solution Approach 2:
PS48 functions as an intermediary compound that indirectly restores insulin signaling through multiple intermediate steps: it enhances insulin receptor sensitivity, improves IRS phosphorylation, and modulates PI3K/Akt activation. This indirect mechanism through multiple intermediaries prevents direct overstimulation of the pathway while achieving the desired therapeutic effect on neuronal viability.
Data Source
AI summary
Provided are compositions and methods useful for sensitizing a neuron to insulin or insulin-like growth factor 1 (IGF-1), wherein the neuron is resistant to either insulin or IGF-1. Also provided are compositions and method useful for inhibiting intracellular beta amyloid peptide Aβ42-mediated decrease in neuronal viability. Also provided are compositions and methods useful for improving synaptic plasticity. Also provided are compositions and methods useful for improving learning and memory. In certain embodiments, the composition comprises (Z)-5-(4-chlorophenyl)-3-phenylpent-2-enoic acid (PS48). In certain embodiments, the method comprises contacting a neuron with PS48. In certain embodiments, the method comprises administering an effective amount of PS48 to a subject in need thereof.